reports
- Laura Chico
- Gary Brode
- Gary Brode
- Laura Chico
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
- Team Pharma
- Team Pharma
Eisai Initiated Rolling Supplemental Biologics License Application to ...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasd...
Biogen and Stoke Therapeutics Present Data at the 36th International E...
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome – Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines – – Zorevunersen generally well tolerat...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection f...
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S. TOKYO and CAMBRIDGE, Mass., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Ca...
- Wedbush Research
- Laura Chico
- Gary Brode
- Dave Nicoski
- Ross LaDuke
PBF PBF ENERGY INC. CLASS A
LEN LENNAR CORPORATION CLASS A
GPRE GREEN PLAINS INC.
GBCI GLACIER BANCORP INC.
FFIC FLUSHING FINANCIAL CORP.
DVN DEVON ENERGY CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CNO CNO FINANCIAL GROUP INC.
CBU COMMUNITY BANK SYSTEM INC.
BIIB BIOGEN INC.
BC BRUNSWICK CORPORATION
HP HELMERICH & PAYNE INC.
PVH PVH CORP.
TTC TORO COMPANY
HOG HARLEY-DAVIDSON INC.
WGO WINNEBAGO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
PRPL PURPLE INNOVATION
GRWG GROWGENERATION
DCOM DIME COMMUNITY BANCSHARES INC
APA APA CORPORATION
AMR ALPHA METALLURGICAL RESOURCES INC
BBWI BATH & BODY WORKS INC
CIVI CIVITAS RESOURCES INC
BORR BORR DRILLING LTD
MBC_w MASTERBRAND INC
NE NOBLE CORP (NEW)
FTREV FORTREA HOLDINGS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.